<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;R01A&quot;,&quot;href&quot;:&quot;atc/R01A.md&quot;},{&quot;label&quot;:&quot;ciclesonide&quot;}]"></div>
<div class="pk-recnav" data-items="[{&quot;id&quot;:&quot;Ciclesonide_Xu2010_reference&quot;,&quot;label&quot;:&quot;Xu_2010_reference&quot;,&quot;group&quot;:&quot;popPK&quot;,&quot;href&quot;:&quot;drugs/drug_ciclesonide/Ciclesonide_Xu2010_reference.md&quot;,&quot;status&quot;:&quot;extracted&quot;,&quot;css&quot;:&quot;pk-badge--green&quot;,&quot;here&quot;:false}]"></div>

# ciclesonide

- **generic name:** ciclesonide
- **ATC codes:** `R01AD13`, `R03BA08`
- **DrugBank:** [DB01410](https://go.drugbank.com/drugs/DB01410) · **PubChem:** [CID 6918155](https://pubchem.ncbi.nlm.nih.gov/compound/6918155)
- **molar mass:** 540.697 g/mol (C32H44O7) — DrugBank
- **groups:** approved, investigational

## About

Ciclesonide is a glucocorticoid used to treat allergic rhinitis and obstructive airway diseases such as asthma. It is an approved medicine, available as a nasal spray and as an inhaler, and is used in routine clinical practice.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q5119448](https://www.wikidata.org/wiki/Q5119448) and the WHO ATC classification; not checked by a person.</small>

## Molecules and molar masses

> The molar mass each model uses to convert mass to molar concentration and to form a metabolite molecule for molecule. Looked up, never estimated: DrugBank for the drug, the paper's own value or the PubChem entry matched to the paper's name for a metabolite.

| molecule | role | molar mass (g/mol) | formula | source | PubChem | records |
|---|---|---|---|---|---|---|
| ciclesonide | parent | 540.697 | C32H44O7 | DrugBank | [6918155](https://pubchem.ncbi.nlm.nih.gov/compound/6918155) | Rohatagi_2003, Rohatagi_2005, Xu_2010 |
| ciclesonide-active principle (CIC-AP) (des-CIC, desisobutyryl-ciclesonide) | metabolite | 470.606 | C28H38O6 | PubChem | [6918281](https://pubchem.ncbi.nlm.nih.gov/compound/6918281) | Rohatagi_2003, Rohatagi_2005, Xu_2010 |

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-07 12:42 | 1:00 | 3/0/0 | 1/1/1 | 0/0/0 | 37,220/6,475 | ollama / glm-5.3-flash | 1 | 1/0 | 1/0 | 0 |

## popPK records

| status | detail | model | model structure | params | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">extracted</span> | [Rohatagi_2003_reference](drugs/drug_ciclesonide/Ciclesonide_Rohatagi2003_reference.md) | held back | 1-compartment, oral | 2 | Rohatagi S et al., Population pharmacokinetics and pharmac…, Journal of clinical pharmac… (2003) | [10.1177/0091270002250998](https://doi.org/10.1177/0091270002250998) |
| <span class="pk-badge pk-badge--green">extracted</span> | [Rohatagi_2005_reference](drugs/drug_ciclesonide/Ciclesonide_Rohatagi2005_reference.md) | held back | 1-compartment, oral | 2 | Rohatagi S et al., Model-based covariate pharmacokinetic a…, American journal of therape… (2005) | [10.1097/01.mjt.0000155110.69831.75](https://doi.org/10.1097/01.mjt.0000155110.69831.75) |
| <span class="pk-badge pk-badge--green">extracted</span> | [Xu_2010_reference](drugs/drug_ciclesonide/Ciclesonide_Xu2010_reference.md) | ▶ model + simulator | 1-compartment, oral | 5 | Xu J et al., Population pharmacokinetics and pharmac…, Journal of clinical pharmac… (2010) | [10.1177/0091270009354994](https://doi.org/10.1177/0091270009354994) |

## Pharmacodynamics (PD)

| status | detail | about | model | citation | doi |
|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">extracted</span> | [Pu_2026_COPD_exacerbations](drugs/drug_ciclesonide/pd_Pu_2026_COPD_exacerbations.md) | COPD exacerbations ← ciclesonide · direct Emax (saturable) effect | — | Pu X et al., Adverse events of inhaled corticosteroi…, BMJ evidence-based medicine (2026) | [10.1136/bmjebm-2024-113216](https://doi.org/10.1136/bmjebm-2024-113216) |
| <span class="pk-badge pk-badge--green">extracted</span> | [Pu_2026_URTI](drugs/drug_ciclesonide/pd_Pu_2026_URTI.md) | upper respiratory tract infection ← ciclesonide · direct Emax (saturable) effect | — | Pu X et al., Adverse events of inhaled corticosteroi…, BMJ evidence-based medicine (2026) | [10.1136/bmjebm-2024-113216](https://doi.org/10.1136/bmjebm-2024-113216) |
| <span class="pk-badge pk-badge--green">extracted</span> | [Pu_2026_all_cause_mortality](drugs/drug_ciclesonide/pd_Pu_2026_all_cause_mortality.md) | all-cause mortality ← ciclesonide · direct Emax (saturable) effect | — | Pu X et al., Adverse events of inhaled corticosteroi…, BMJ evidence-based medicine (2026) | [10.1136/bmjebm-2024-113216](https://doi.org/10.1136/bmjebm-2024-113216) |
| <span class="pk-badge pk-badge--green">extracted</span> | [Pu_2026_asthma_exacerbations](drugs/drug_ciclesonide/pd_Pu_2026_asthma_exacerbations.md) | asthma exacerbations ← ciclesonide · direct Emax (saturable) effect | — | Pu X et al., Adverse events of inhaled corticosteroi…, BMJ evidence-based medicine (2026) | [10.1136/bmjebm-2024-113216](https://doi.org/10.1136/bmjebm-2024-113216) |
| <span class="pk-badge pk-badge--green">extracted</span> | [Pu_2026_cataract](drugs/drug_ciclesonide/pd_Pu_2026_cataract.md) | cataract ← ciclesonide · direct Emax (saturable) effect | — | Pu X et al., Adverse events of inhaled corticosteroi…, BMJ evidence-based medicine (2026) | [10.1136/bmjebm-2024-113216](https://doi.org/10.1136/bmjebm-2024-113216) |
| <span class="pk-badge pk-badge--green">extracted</span> | [Pu_2026_diabetes](drugs/drug_ciclesonide/pd_Pu_2026_diabetes.md) | diabetes ← ciclesonide · direct Emax (saturable) effect | — | Pu X et al., Adverse events of inhaled corticosteroi…, BMJ evidence-based medicine (2026) | [10.1136/bmjebm-2024-113216](https://doi.org/10.1136/bmjebm-2024-113216) |
| <span class="pk-badge pk-badge--green">extracted</span> | [Pu_2026_fracture](drugs/drug_ciclesonide/pd_Pu_2026_fracture.md) | fracture ← ciclesonide · direct Emax (saturable) effect | — | Pu X et al., Adverse events of inhaled corticosteroi…, BMJ evidence-based medicine (2026) | [10.1136/bmjebm-2024-113216](https://doi.org/10.1136/bmjebm-2024-113216) |
| <span class="pk-badge pk-badge--green">extracted</span> | [Pu_2026_oral_candidiasis](drugs/drug_ciclesonide/pd_Pu_2026_oral_candidiasis.md) | oral candidiasis ← ciclesonide · direct Emax (saturable) effect | — | Pu X et al., Adverse events of inhaled corticosteroi…, BMJ evidence-based medicine (2026) | [10.1136/bmjebm-2024-113216](https://doi.org/10.1136/bmjebm-2024-113216) |
| <span class="pk-badge pk-badge--green">extracted</span> | [Pu_2026_plasma_cortisol_abnormalities](drugs/drug_ciclesonide/pd_Pu_2026_plasma_cortisol_abnormalities.md) | plasma cortisol abnormalities ← ciclesonide · direct Emax (saturable) effect | — | Pu X et al., Adverse events of inhaled corticosteroi…, BMJ evidence-based medicine (2026) | [10.1136/bmjebm-2024-113216](https://doi.org/10.1136/bmjebm-2024-113216) |
| <span class="pk-badge pk-badge--green">extracted</span> | [Pu_2026_pneumonia](drugs/drug_ciclesonide/pd_Pu_2026_pneumonia.md) | pneumonia ← ciclesonide · direct Emax (saturable) effect | — | Pu X et al., Adverse events of inhaled corticosteroi…, BMJ evidence-based medicine (2026) | [10.1136/bmjebm-2024-113216](https://doi.org/10.1136/bmjebm-2024-113216) |
| <span class="pk-badge pk-badge--orange">needs review</span> | [Rohatagi_2003_cortisol](drugs/drug_ciclesonide/pd_Rohatagi_2003_cortisol.md) | endogenous cortisol ← ciclesonide--active principle (CIC-AP) · indirect response — drug inhibits the production of endogenous cortisol | model (no simulator) | Rohatagi S et al., Population pharmacokinetics and pharmac…, Journal of clinical pharmac… (2003) | [10.1177/0091270002250998](https://doi.org/10.1177/0091270002250998) |
| <span class="pk-badge pk-badge--red">rejected</span> | [Rohatagi_2005_cortisol](drugs/drug_ciclesonide/pd_Rohatagi_2005_cortisol.md) | circadian endogenous cortisol release ← des-CIC (C21-desisobutyryl-ciclesonide) · direct Emax (saturable) effect | — | Rohatagi S et al., Model-based covariate pharmacokinetic a…, American journal of therape… (2005) | [10.1097/01.mjt.0000155110.69831.75](https://doi.org/10.1097/01.mjt.0000155110.69831.75) |

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=ciclesonide) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| absorption | liver | <sub>named in DrugBank's ADME text</sub> | prose |
| metabolism | brain | `CYP2D6` substrate | DrugBank actor |
| metabolism | liver | `CES1` substrate, `CYP2D6` substrate, `CYP3A4` substrate | DrugBank actor |
| metabolism | small intestine | `CYP3A4` substrate | DrugBank actor |

<sub>Actors without a tissue in the table: NR3C1 (target), SERPINA6 (binder).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>the data come from an animal (or in-vitro) study, not from people. The record, its model and its simulation are kept — they describe that species.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 7 matched, 7 returned
- **screened:** 3  ·  **relevant:** 3
- **records:** 3  ·  extracted 3  ·  needs_review 0  ·  rejected 0  ·  stale 0
- **scholar-agent fallback query used:** not captured

## Full text wanted

_3 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Rohatagi_2003.pdf` | Rohatagi S et al., Population pharmacokinetics and pharmac…, Journal of clinical pharmac… (2003) | popPK | 10 | [10.1177/0091270002250998](https://doi.org/10.1177/0091270002250998) | [12723457](https://pubmed.ncbi.nlm.nih.gov/12723457) | Population PK model of ciclesonide's active metabolite (CIC-AP) with numeric CL and V values reported directly in the abstract. |
| `Rohatagi_2005.pdf` | Rohatagi S et al., Model-based covariate pharmacokinetic a…, American journal of therape… (2005) | popPK | 10 | [10.1097/01.mjt.0000155110.69831.75](https://doi.org/10.1097/01.mjt.0000155110.69831.75) | [16148423](https://pubmed.ncbi.nlm.nih.gov/16148423) | Population PK of des-CIC (active metabolite of ciclesonide) with numeric CL (302 L/h) and V (1310 L) reported in the abstract; ka and full parameter table may be in the paper body. |
| `Xu_2010.pdf` | Xu J et al., Population pharmacokinetics and pharmac…, Journal of clinical pharmac… (2010) | popPK | 10 | [10.1177/0091270009354994](https://doi.org/10.1177/0091270009354994) | [20150524](https://pubmed.ncbi.nlm.nih.gov/20150524) | Population PK model of Des-CIC (active metabolite of ciclesonide) with numeric ka, CL, and V reported directly in the abstract. |

<sub>queue written 2026-10-07T12:41:38.819272+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| popPK | Pu_2026 | irrelevant | 0 | 0 | This is a safety meta-analysis of inhaled corticosteroids; ciclesonide appears only as a comparator with no PK parameters reported. |
| popPK | Sanz_2025 | irrelevant | 0 | 0 | This is a clinical efficacy study of inhaled ciclesonide in horses with asthma; no PK parameters (CL, V, ka, half-life, or PK model) are reported anywhere in the evidence. |

---
<sub>Generated by `docs.py` (scholarv2) · newest extraction 2026-10-07 12:41 UTC</sub>
